Obstetrics. & Gynecology
Permanent URI for this communityhttps://repository.ibadanedu.com/handle/123456789/525
Browse
4 results
Search Results
Item Mutation analysis of p53 gene in cervical cancer and useful polymorphic variants in exons 3 and 4(2021) Gbadegesin, M. A.; Omotosho, O. E.; Oluwasola, T. A. O.; Okolo, C. A.; Oluwasola, A. O.; Soremekun, O.; Ogun, G. O.; Abideen O. O.; Oyeronke A. O.Background: Factors contributing to the pathogenesis and progression of cervical cancer include poor attitude to screening and health intervention, late presentation, among others. Mutations in p53 gene have been attributed to several cancer cases. The present study was designed to find relationships between the mutation patterns in p53 gene and cervical carcinoma staging. Such knowledge could contribute to early diagnosis of cervical cancer. Results: From the sequence analysis of p53 gene fragment isolated by polymerase chain reactions (PCR), nineteen (19) polymorphic variants were identified. Missense mutations occurred in 47% of the samples, 32% were silent mutations, 16% were frameshift mutations and 5% nonsense mutations. Socio-biological characteristics of the study participants revealed that 60% have husbands with multiple sexual partners and that only 23.3% of the participants have ever had the Papanicolaou (Pap) smear test prior to diagnosis, whilst 20% were unaware of the screening test. Conclusions: Increased severity of cervical carcinoma staging as revealed from the histopathological analysis was found to be associated with accumulation of higher levels of mutations in the p53 gene. Molecular analysis of p53 gene mutations may prove useful as a screening biomarker for cervical cancer.Item An overview of the genetics of cervical cancer.(2018) Gbadegesin, M. A.; Soremekun, O.; Oluwasola, T. A. O.; Okolo, C. A.; Oluwasola, A. O.Cervical cancer is the fourth most common cancer in women, and the seventh of all human cancers. It is the most rampant cancer of the female genital tract in the developing world and manifests in two common histological subtypes: squamous cell carcinoma which is derived from squamous cells of the cervix and cervical adenocarcinoma which arose from the glandular cells. Most cases of deaths from cervical cancer occur in the less developed countries of the world where there are ineffective screening systems. Factors that increase the risk for developing cervical cancer include infection by Human Papilloma Virus (HPV) as the main direct factor and other indirect factors such as smoking, dietary habits, age, race, socioeconomic status, sexual history, use of oral contraceptives, high parity and the human immunodeficiency virus infection. Identifying the genetic alterations that predispose to or associate with cervical cancer will help in the screening of patients at risk of the cancer thereby allowing early diagnosis and prompt management with better outcomes. In this review we describe the role of HPV DNA integration into the host cellular genome, the effects of viral E6 and E7 proteins, and the loss of heterozygosity as genetic factors in cervical cancer.Item Pattern of triple negative epithelial ovarian cancer in indigenous African women(2016) Ajani, M. A.; Salami, A. A.; Awolude, O. A.; Oluwasola, A. O.Background: Triple negative epithelial ovarian cancer (TNEOC) refers to ovarian carcinomas that do not express estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor- type 2 (HER-2/neu). The aim of this study is to determine the pattern of triple negative epithelial ovarian cancer in indigenous African women. Methods: We performed a retrospective review of ER, PR and HER-2/neu expression in 90 Nigerian patients with histologically diagnosed epithelial ovarian cancer. Lack of expression of ER, PR and HER2/neu antigens was used to determine carcinomas that are among the TNEOC. We also compared the clinicopathological parameters (age, International Federation of Gynaecology and Obstetrics (FIGO) stage, grade and histological subtype) in patients with TNEOC and non- TNEOC . Results: Thirty-eight (42.2%) of the 90 tumours diagnosed as EOC were negative for ER, PR and HER2/neu expression. There was no significant association between TNEOC with other parameters such as age, FIGO stage and histological grade. Sixteen (66.7%) of the 24 mucinous carcinomas were triple negative, while only 21 (33.3%) of the 63 serous carcinomas were triple-negative and one (50%) of the two endometrioid carcinomas was triple negative. There was a significant association between triple-negative tumours and histological subtypes of EOC (p = 0.034). Conclusions: A subtype of epithelial ovarian cancer that is negative for ER, PR and HER-2/neu has been discovered in indigenous African women. TNEOC expression is high and is comparable to the triple negative breast cancer subtype seen in people of African ancestry. Future study of TNEOC in a large sample size should be considered.Item The expression status of human epidermal growth factor receptor 2 in epithelial ovarian cancer in Ibadan, Nigeria(2016) Ajani, M. A.; Salami, A.; Awolude, O. A.; Oluwasola, A. O.; Akang, E. E. U.Background: It has been proposed that the overexpression of the human epidermal growth factor receptor 2 (HER2/neu protooncogene) could be a possible therapeutic target in epithelial ovarian cancer, as has been the case in breast carcinomas. However, there is lack of knowledge on the status of the gene in neoplasms which occur in black women. The objective of this study was to determine HER2/neu expression status in EOC in black women. Method: Ninety cases of EOC were evaluated for HER2/neu protein expression using immunohistochemistry. Results: HER-2/neu expression was observed in 33 of the 90 cases (37%), of which 15 EOC cases (17%) were weakly or moderately positive, and 18 (20%) strongly positive. A significant association was not found between HER-2/neu expression and age, International Federation of Gynecologists and Obstetrics (FIGO) stage, grading and histological subtypes (p-values of 0.463, 0.360, 0.975 and 0.168, respectively). However, there were more cases of advanced-stage disease (III/IV) with HER-2 expression than early-stage EOC (I/II). In this study, 21%, 36% and 42% of HER2/neu-positive tumours were grades 1, 2 and 3, respectively. A higher proportion of serous carcinomas (as opposed to mucinous carcinomas) was also observed to be ER2/neu positive. Conclusion: HER2/neu expression was observed to increase with advanced stages of cancer, and was more commonly seen in serous, rather than in mucinous, carcinomas.